cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (hiv-1) inhibitor nb325 in a murine modelcervicovaginal制定的安全,biguanide-based人类免疫缺陷病毒1型(hiv - 1)抑制剂nb325小鼠模型.pdfVIP

Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology Volume 2011, Article ID 941061, 10 pages doi:10.1155/2011/941061 Research Article Cervicovaginal Safety of the Formulated, Biguanide-Based Human Immunodeficiency Virus Type 1 (HIV-1) Inhibitor NB325 in a Murine Model Karissa Lozenski,1 Tina Kish-Catalone,2 Vanessa Pirrone,1 Robert F. Rando,3, 4 Mohamed Labib,3 Brian Wigdahl,1 and Fred C. Krebs1 1 Department of Microbiology and Immunology, and Center for Molecular Therapeutics and Resistance, Center for Sexually Transmitted Disease, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, 245 N. 15th Street, Philadelphia, PA 19102, USA 2 Department of Natural Sciences, DeSales University, Center Valley, PA 18034, USA 3 Novaflux Biosciences, Inc., Princeton, NJ 08540, USA 4 Medisys Health Communications, LLC, High Bridge, NJ 08829, USA Correspondence should be addressed to Fred C. Krebs, fkrebs@ Received 16 May 2011; Revised 4 August 2011; Accepted 11 August 2011 Academic Editor: Anthony L. DeVico Copyright © 2011 Karissa Lozenski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Vaginal microbicides that reduce or eliminate the risk of HIV-1 sexual transmission must do so safely without adversely affecting the integrity of the cervicovaginal epithelium. The present studies were performed to assess the safety of the biguanide-based antiviral compound NB325 in a formulation suitable for topical application. Experiments were performed using a mouse model of cervicovaginal microbicide applicat